Combined vitrectomy and intravitreal injection versus combined laser and injection for treatment of intractable diffuse diabetic macular edema

Clinical Ophthalmology

Volumn 7, Issue , 2013, Pages 283-297

  Saeed, Ahmed M ^a  

^a BENHA UNIVERSITY   (Egypt)

Author keywords

Bevacizumab injection; Central foveal thickness; Intractable diffuse diabetic macular edema; Intravitreal triamcinolone; Macular grid laser photocoagulation

Indexed keywords

BEVACIZUMAB; HEMOGLOBIN A1C; TRIAMCINOLONE ACETONIDE;

ADULT; ARTICLE; CATARACT; CILIARY DISK; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLOW UP; HEALTH CARE AVAILABILITY; HUMAN; INTRAOCULAR HYPERTENSION; LASER COAGULATION; MALE; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PATIENT SAFETY; RANDOMIZED CONTROLLED TRIAL; RETINA FOVEA; VISUAL ACUITY; VITRECTOMY; VITREOSCHISIS; VITREOUS DISEASE;

EID: 84874795671     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/opth.s37781     Document Type: Article

References (48)

1. National Society to Prevent Blindness. Visual problems in the US Data Analysis Definition, Data Sources, Detailed Data Tables, Analysis, and Interpretation. New York, NY: National Society to Prevent Blindness; 1980.
2. Williams R, Airey M, Baxter H. Epidemiology of diabetic retinopathy and macular edema: a systematic review. Eye. 2004;18:963-983.
3. Kubawara T, Cogan DG. Retinal vascular patterns VI: mural cells of the retinal capillaries. Arch Ophthalmol. 1962;69:492-502.
4. Williamson JR, Kilo C. Extracellular matrix changes in diabetes mel-litus. In: Scarpelli DG, Migahi DG, editors. Comparative Pathobiology of Major Age-Related Diseases. New York, NY: Liss; 1984.
5. Ferris FL III, Patz A. Macular edema: a complication of diabetic retin-opathy. Surv Ophthalmol. 1984;28:452-461.
6. Gandorfer A, Messmer EM, Ulbig MW, Kampik A. Resolution of diabetic macular edema after surgical removal of the posterior hyaloid and the inner limiting membrane. Retina. 2000;20:126-133.
7. Hikichi T, Fujio N, Akiba J, Azuma Y, Takahashi M, Yoshida A. Association between the short-term natural history of diabetic macular edema and the vitreomacular relationship in type II diabetes mellitus. Ophthalmology. 1997;104:473-478.
8. Ikeda T, Sato K, Katano T, Hayashi Y. Vitrectomy for cystoid macular oedema with attached posterior hyaloid membrane in patients with diabetes. Br J Ophthalmol. 1999;83:12-14.
9. Ikeda T, Sato K, Katano T, Hayashi Y. Improved visual acuity following pars plana vitrectomy for diabetic cystoid macular edema and detached posterior hyaloid. Retina. 2000;20:220-222.
10. Lewis H, Abrams GW, Blumenkranz MS, Campo RV. Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology. 1992;99:753-759.
11. Nasrallah FP, Jalkh AE, van Coppenolle F, et al The role of the vitreous in diabetic macular edema. Ophthalmology. 1998;95:1335-1339.
12. Pendergast SD, Hassan TS, Williams GA, et al. Vitrectomy for diffuse diabetic macular edema associated with a taut premacular posterior hyaloid. Am J Ophthalmol. 2000;130:178-186.
13. Stefánsson E. Physiology of vitreous surgery. Graefes Arch Clin Exp Ophthalmol. 2009;247:147-163.
14. Hartley KL, Smiddy WE, Flynn HW Jr, Murray TG. Pars plana vitrectomy with internal limiting membrane peeling for diabetic macular edema. Retina. 2008;28:410-419.
15. Harbour JW, Smiddy WE, Flynn HW, Rubsamen PE. Vitrectomy for diabetic macular edema associated with a thickened and taut posterior hyaloid membrane. Am J Ophthalmol. 1996;121:405-413.
16. Heij EC, Hendrikse F, Kessels AG, Derhaag PJ. Vitrectomy results in diabetic macular oedema without evident vitreomacular traction. Graefes Arch Clin Exp Ophthalmol. 2001;239:264-270.
17. Yanyali A, Horozoglu F, Celik E, Nohutcu AF. Long-term outcomes of pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema. Retina. 2007;27:557-566.
18. Klein R, Klein B, Moss S. Visual impairment in diabetes. Ophthalmology. 1984;91:1-8.
19. The Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report No 1. Arch Ophthalmol. 1985;103:1796-1806.
20. Dillinger P, Mester U. Vitrectomy with removal of the internal limiting membrane in chronic diabetic macular oedema. Graefes Arch Clin Exp Ophthalmol. 2004;242:630-637.
21. Figueroa MS, Contreras I, Noval S. Surgical and anatomical outcomes of pars plana vitrectomy of diffuse nontractional diabetic macular edema. Retina. 2008;28:420-426.
22. Kuhn F, Kiss G, Mester V, et al. Vitrectomy with internal limiting membrane removal for clinically significant macular oedema. Graefes Arch Clin Exp Ophthalmol. 2004;242:402-408.
23. Rosenblatt BJ, Benson WE. Diabetic retinopathy. In: Yanoff M, Duker JS, editors. Ophthalmology, 2nd ed. St Louis, MO: Mosby; 2004.
24. Kent D, Vinores S, Campochiaro P. Macular edema: the role of soluble mediators. Br J Ophthalmol. 2000;84:542-545.
25. Kishi S, Shimizu K. Posterior vitreous precortical pocket. Arch Ophthalmol. 1990;108:979-982.
26. Tachi N, Ogino N. Vitrectomy for diffuse macular edema in cases of diabetic retinopathy. Am J Ophthalmol. 1996;122:258-260.
27. Stefánsson E, Novack RL, Hatchell DL. Vitrectomy prevents hypoxia in branch retinal vein occlusion. Invest Ophthalmol Vis Sci. 1990;31: 284-289.
28. Stefánsson E. Therapeutic effects of retinal laser treatment and vitrectomy. A theory based on oxygen and vascular physiology. Acta Ophthalmol Scand. 2001;79:435-440.
29. Recchia FM, Ruby AJ, Carvalho Recchia CA. Pars plana vitrectomy with removal of the internal limiting membrane in the treatment of persistent diabetic macular edema. Am J Ophthalmol. 2005;139:447-454.
30. Rosenblatt BJ, Shab GK, Sharma S, Bakal J. Pars plana vitrectomy with internal limiting membranectomy for refractory diabetic macular edema without a taut posterior hyaloid. Graefes Arch Clin Exp Ophthalmol. 2005;243:20-25.
31. Stolba U, Binder S, Gruber D, Krebs I, Aggermann T, Neumaier B. Vitrectomy for persistent diffuse diabetic macular edema. Am J Ophthalmol. 2005;140:295-301.
32. Bahadir M, Ertan A, Mertoglu O. Visual acuity comparison of vitrectomy with and without internal limiting membrane removal in the treatment of diabetic macular edema. Int Ophthalmol. 2005;26:3-8.
33. Yamamoto T, Hitani K, Sato Y, et al. Pars plana vitrectomy with and without peeling of the inner limiting membrane for diabetic macular edema. Ophthalmologica. 2005;219:206-213.
34. Song JS, Sohn JH, Park KH. Evaluation of the efficacy of vitrectomy for persistent diabetic macular edema and associated factors predicting outcome. Korean J Ophthalmol. 2007;21:146-150.
35. Shah S, Patel M, Thomas D, et al. Factors predicting outcome of vitrectomy for diabetic macular oedema: results of a prospective study. Br J Ophthalmol. 2006;90:33-36.
36. Jonas JB, Spandau UH, Kamppeter BA, Vossmerbaeumer U, Harder B. Follow-up after intravitreal triamcinolone acetonide for diabetic macular edema. Eur J Ophthalmol. 2006;16:566-572.
37. Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology. 2006;113:1533-1538.
38. Haritoglou C, Kook D, Neubauer A, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina. 2006;26:999-1005.
39. Kumar A, Sinha S, Azad R, Sharma YR, Vohra R. Comparative evaluation of vitrectomy and dye-enhanced ILM peel with grid laser in diffuse diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2007;245:360-368.
40. Soheilian M, Ramezani A, Bijanzadeh B, et al. Intravitreal bevacizumab (Avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina. 2007;27:1187-1195.
41. Faghihi H, Roohipoor R, Mohammadi SF, et al. Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema. Eur J Ophthalmol. 2008;18:941-948.
42. Kumar V, Ghosh B, Raina UK, Goel N. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol. 2008;146: 974-975.
43. Soheilian M, Garfami KH, Ramezani A, et al. Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina. 2012;32: 314-321.
44. Steijns D, Duijvesz D, Breedijk MA, van der Heijden GJ. Steroid injection in addition to macular laser grid photocoagulation in diabetic macular oedema: a systematic review. Acta Ophthalmol. 2010;88: 389-393.
45. Mohan R, Murlidharan AR. Steroid induced glaucoma and cataract. Indian J Ophthalmol. 1989;15:80-84.
46. Almeida DR, Johnson D, Hollands H, et al. Effect of prophylactic nonsteroidal antiinflammatory drugs on cystoid macular edema assessed using optical coherence tomography quantification of total macular volume after cataract surgery. J Cataract Refract Surg. 2008;34: 64-69.
47. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina. 2000;20:244-250.
48. Furino C, Micelli Ferrari T, Boscia F, Cardascla N, Recchimurzo N, Sborgia C. Triamcinolone-assisted pars plana vitrectomy for proliferative vitreoretinopathy. Retina. 2003;23:771-776.